BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35963815)

  • 1. Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment.
    Huo W; Yang X; Wang B; Cao L; Fang Z; Li Z; Liu H; Liang XJ; Zhang J; Jin Y
    Biomaterials; 2022 Sep; 288():121722. PubMed ID: 35963815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
    Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
    Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
    Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
    Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of pH-Sensitive Nanovaccines Encapsulating Tumor Cell Lysates and Immune Adjuvants for Breast Cancer Therapy.
    Ding Y; Yang J; Wei H; Wang J; Huang S; Yang S; Guo Y; Li B; Shuai X
    Small; 2023 Sep; 19(37):e2301420. PubMed ID: 37154213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
    Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
    ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy.
    Yang A; Sheng S; Bai Y; Xing G; Yu X; Zhu D; Mei L; Dong X; Lv F
    Acta Biomater; 2022 Nov; 153():124-138. PubMed ID: 36179979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy.
    Liang JL; Jin XK; Luo GF; Zhang SM; Huang QX; Lin YT; Deng XC; Wang JW; Chen WH; Zhang XZ
    ACS Nano; 2023 Sep; 17(17):17217-17232. PubMed ID: 37584451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy.
    Lei L; Huang D; Gao H; He B; Cao J; Peppas NA
    Sci Adv; 2022 Nov; 8(47):eadc8738. PubMed ID: 36427310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
    Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
    Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
    Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH
    Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
    Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
    Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome transportation-mediated immunosuppression relief through cascade amplification for enhanced apoptotic body vaccination.
    Zhao G; Liu H; Wang Z; Yang H; Zhao H; Zhang Y; Ge K; Wang X; Luo L; Zhou X; Zhang J; Li Z
    Acta Biomater; 2022 Nov; 153():529-539. PubMed ID: 36113726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A programmable releasing versatile hydrogel platform boosts systemic immune responses via sculpting tumor immunogenicity and reversing tolerogenic dendritic cells.
    Fu W; Li X; Li Y; Luo R; Ou C; Huang D; Liang X; You Y; Wu Q; Gong C
    Biomaterials; 2024 Mar; 305():122444. PubMed ID: 38142471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
    Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
    J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.
    Wang H; Najibi AJ; Sobral MC; Seo BR; Lee JY; Wu D; Li AW; Verbeke CS; Mooney DJ
    Nat Commun; 2020 Nov; 11(1):5696. PubMed ID: 33173046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
    Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M
    Front Immunol; 2022; 13():938439. PubMed ID: 35812418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment.
    Lv F; Liu H; Zhao G; Zhao E; Yan H; Che R; Yang X; Zhou X; Zhang J; Liang XJ; Li Z
    iScience; 2022 Jan; 25(1):103639. PubMed ID: 35024580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.